该职位来源于猎聘
- 评估和制定公司所有投资组合产品的整体市场准入策略,包括国家和省级市场准入策略。
- 制定全生命周期内所有产品组合的定价和医保策略。
- 识别市场准入的风险和机会,并制定对策。
- 领导本地市场准入证据生成工作,确保业务实施中的证据质量和认可度。
- 为业务规划提供及时的市场准入政策环境分析
- 制定、领导和协调所有市场准入项目的策略,如NRDL(国家报销药品目录)、CHI和EAP等。
- 生成有利的政策证据,以支持所有市场准入活动和目标,如医保、医院列名等。
- 开发和领导中国所有投资组合产品的HTA(医疗技术评估)和HE(健康经济)计划和项目,包括国外模型的本地化和本地项目开发,以支持业务优化。
- 在内部发挥积极作用,协调跨职能合作,并嵌入与业务绩效一致的市场准入战略。 Assess and develop the whole market access strategy of company all portfolios both on national level and provincial level.
- Develop pricing and reimbursement strategy for all portfolios through the whole lifecycle.
- Identify the risks and opportunities of market access and develop the countermeasures.
- Lead the local market access evidence generation and ensure the evidence quality and recognition in the business implementation.
- Provide timely market access policy environment analysis for business planning.
- Develop and Lead and Coordinate the strategy of all market access projects, like NRDL (National Reimbursement Drug List) and CHI and EAP, etc...
- Generate favourable policy evidence to support all market access activities and targets, like reimbursement, hospital listing, etc.
- Develop and lead the HTA (Healthcare Technology Assessment) and HE (Health Economic) initiatives of all portfolios in China, including the global model local adaptation and local project development to support business optimization.
- Play active role internally to coordinate the cross-functional cooperation and embed the market access strategy aligned with business performance. 任职资格:
- 本科及以上学历,医学、药学专业背景优先
- 5-7年以上跨国制药公司相关工作经验
- 优秀的谈判和政策分析能力,良好的沟通能力
- 以结果为导向,亲力亲为,独立性强,能承受工作压力
- 有很好的英语沟通能力,包括听说读写。
- Bachelor's degree at least, major in Medical, Pharm background is preferable
- Minimum 5-7 year's solid similar working experience with multinational pharmaceutical company
- Excellent lobbying and policy analysis skills and good communication
- Result-oriented, hands-on, independent and be able to work under pressure
- Bi-lingual capability, Chinese and English, reading and writing is basic.